Short answer
Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 8.01 (Other Events). FDA clearance enables VY1706’s first-in-human development for tau pathology in early Alzheimer’s disease.
Voyager Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA clearance enables VY1706’s first-in-human development for tau pathology in early Alzheimer’s disease
- Multi-site, open-label dose-escalation trial planned for second half of 2026
- Up to 18 patients across three cohorts, with one-time intravenous dosing
- Primary endpoint safety and tolerability; secondary measures include cerebrospinal fluid tau biomarkers and tau PET imaging
- Key investor risks include enrollment, safety, efficacy, regulatory timing, manufacturing, and cash sufficiency
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Voyager Therapeutics, Inc. 8-K filings
Get the next VYGR 8-K as it lands
Follow VYGR for push alerts, or ask the research agent what this filing means.